Seasons Hospice & Palliative Care 5775 Peachtree Dunwoody Road Ne Suite C-120, Atlanta, GA, 30342 | |
(404) 250-4950 |
News Archive
Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.
Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.
During a normal monthly health physics check, the radiation monitoring badge of an Australian Nuclear Science and Technology Organisation (ANSTO) worker recently registered an unusual dose of 66 millisieverts or the equivalent of five abdominal CT scans. Other workers' badges were normal.
Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.
Edgbaston Medical Quarter (EMQ) will be at Arab Health 2017 for the first time to showcase the healthcare and life sciences revolution taking place in the West Midlands, in the heart of the UK.
› Verified 5 days ago
Name | Seasons Hospice & Palliative Care |
---|---|
Location | 5775 Peachtree Dunwoody Road Ne Suite C-120, Atlanta, Georgia |
Hospice ID | 111640 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
SSA county code | 470 |
News Archive
Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.
Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.
During a normal monthly health physics check, the radiation monitoring badge of an Australian Nuclear Science and Technology Organisation (ANSTO) worker recently registered an unusual dose of 66 millisieverts or the equivalent of five abdominal CT scans. Other workers' badges were normal.
Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.
Edgbaston Medical Quarter (EMQ) will be at Arab Health 2017 for the first time to showcase the healthcare and life sciences revolution taking place in the West Midlands, in the heart of the UK.
› Verified 5 days ago
NPI Number | 1336163815 |
Organization Name | Embracing Hospicecare, Llc |
Address | 5775 Peachtree Dunwoody Rd Ne Atlanta, Georgia, 30342 |
Phone Number | (404)659-0110 |
News Archive
Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.
Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.
During a normal monthly health physics check, the radiation monitoring badge of an Australian Nuclear Science and Technology Organisation (ANSTO) worker recently registered an unusual dose of 66 millisieverts or the equivalent of five abdominal CT scans. Other workers' badges were normal.
Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.
Edgbaston Medical Quarter (EMQ) will be at Arab Health 2017 for the first time to showcase the healthcare and life sciences revolution taking place in the West Midlands, in the heart of the UK.
› Verified 5 days ago
NPI Number | 1790080950 |
Organization Name | Seasons Hospice & Palliative Care Of Georgia, Llc |
Address | 5775 Peachtree Dunwoody Rd Ne Atlanta, Georgia, 30342 |
Phone Number | (847)692-1000 |
News Archive
Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.
Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.
During a normal monthly health physics check, the radiation monitoring badge of an Australian Nuclear Science and Technology Organisation (ANSTO) worker recently registered an unusual dose of 66 millisieverts or the equivalent of five abdominal CT scans. Other workers' badges were normal.
Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.
Edgbaston Medical Quarter (EMQ) will be at Arab Health 2017 for the first time to showcase the healthcare and life sciences revolution taking place in the West Midlands, in the heart of the UK.
› Verified 5 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.3 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 95.6 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 92.2 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 95.6 | 97.3 |
Patients who got timely treatment for shortness of breath | 96.8 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 98.5 | 93.3 |
News Archive
Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.
Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.
During a normal monthly health physics check, the radiation monitoring badge of an Australian Nuclear Science and Technology Organisation (ANSTO) worker recently registered an unusual dose of 66 millisieverts or the equivalent of five abdominal CT scans. Other workers' badges were normal.
Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.
Edgbaston Medical Quarter (EMQ) will be at Arab Health 2017 for the first time to showcase the healthcare and life sciences revolution taking place in the West Midlands, in the heart of the UK.
› Verified 5 days ago
Home Health Aides | 8 |
Counselors | 1 |
Licensed Practical or Vocational Nurses | 2 |
Medical Social Workers | 3 |
Registered Nurses | 14 |
Other Personnel | 14 |
Total Employees | 42 |
---|
News Archive
Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.
Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.
During a normal monthly health physics check, the radiation monitoring badge of an Australian Nuclear Science and Technology Organisation (ANSTO) worker recently registered an unusual dose of 66 millisieverts or the equivalent of five abdominal CT scans. Other workers' badges were normal.
Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.
Edgbaston Medical Quarter (EMQ) will be at Arab Health 2017 for the first time to showcase the healthcare and life sciences revolution taking place in the West Midlands, in the heart of the UK.
› Verified 5 days ago
Others | 22 |
Total Volunteers | 22 |
---|
News Archive
Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.
Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.
During a normal monthly health physics check, the radiation monitoring badge of an Australian Nuclear Science and Technology Organisation (ANSTO) worker recently registered an unusual dose of 66 millisieverts or the equivalent of five abdominal CT scans. Other workers' badges were normal.
Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.
Edgbaston Medical Quarter (EMQ) will be at Arab Health 2017 for the first time to showcase the healthcare and life sciences revolution taking place in the West Midlands, in the heart of the UK.
› Verified 5 days ago
Hospice Atlanta Location: 1244 Park Vista Dr., Atlanta, Georgia, 30319 Phone: (404) 250-4950 |
Aseracare Hospice Location: 1117 Perimeter Center West, Suite N500, Atlanta, Georgia, 30338 Phone: (404) 250-4950 |
Gentiva Hospice Location: 3101 Towercreek Pkwy Se Suite 225, Atlanta, Georgia, 30339 Phone: (404) 250-4950 |
Vitas Healthcare Corporation Of Georgia Location: 1575 Northside Drive, Suite 375, Atlanta, Georgia, 30318 Phone: (404) 250-4950 |